CREATE Medicines Inc., a clinical-stage biotechnology company pioneering in vivo multi-immune programming, today announced ...
IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across ...
In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a ...
Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...
Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.
Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference December 8, 2025 8:00 ...
In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy blood-forming cells. If the disease ...
Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards ...
Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...
Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback